Tanezumab in Osteoarthritis of the Knee
- Conditions
- ArthritisOsteoarthritis
- Interventions
- Biological: PlaceboBiological: tanezumab
- Registration Number
- NCT00733902
- Lead Sponsor
- Pfizer
- Brief Summary
Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 697
- Osteoarthritis of the knee according to ACR criteria with a Kellgren-Lawrence x-ray grade of 2.
- Unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for knee injections arthroplasty or replace surgery.
- Pain level and function levels as required by the protocol at Screening and Baseline.
- Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study.
- Must agree to the contraceptive requirements of the protocol if applicable.
- Must agree to the treatment plan, scheduled visits, and procedures of the protocol.
- Pregnancy or intent to become pregnant during the study
- BMI greater than 39
- other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Tanezumab 10 mg tanezumab - Tanezumab 5 mg tanezumab - Tanezumab 2.5 mg tanezumab -
- Primary Outcome Measures
Name Time Method Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 16: Baseline Observation Carried Forward (BOCF) Baseline, Week 16 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF) Baseline (Day 1), Week 16 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF) Baseline, Week 16 Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF) Week 2, 4, 8, 12, 16, 24 OMERACT-OARSI response: \>= 50% improvement from baseline and absolute change from baseline of \>=2 units at Week of interest in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: \>=20% improvement from baseline and absolute change from baseline of \>=1 unit at Week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0-10, higher score=higher pain/difficulty).
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF) Baseline, Week 2, 4, 8, 12, 16, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 2, 4, 8, 12, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living
Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF) Week 2, 4, 8, 12, 16, 24 OMERACT-OARSI response: greater than or equal to (\>=) 50 percent (%) improvement from baseline and absolute change from baseline of \>=2 units at Week of interest in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: \>=20% improvement from baseline and absolute change from baseline of \>=1 unit at Week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0-10, higher score=higher pain/difficulty).
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item at Week 2, 4, 8, 12, 16, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 16, 24 Participants answered, Question (Q)1: "How much pain have you had when walking on a flat surface?" and Q2: "How much pain have you had when going up or down the stairs?". Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF) Baseline, Week 2, 4, 8, 12, 16, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8, 12, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF) Baseline, Week 2, 4, 8, 12, 16, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscales at Week 2, 4, 8, 12, 16, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 16, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee.
Percentage of Participants With at Least 30 Percent (%) and 50% Reduction From Baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF) Baseline, Week 2, 4, 8, 12, 16, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.
Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 16, 24 Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 24 Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF) Baseline, Week 2, 4, 8, 12, 16, 24 Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.
Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis: Last Observation Carried Forward (LOCF) Baseline, Week 2, 4, 8, 12, 16, 24 Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.
Time to Discontinuation Due to Lack of Efficacy Baseline up to Week 16 Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.
Duration of Rescue Medication Use Week 2, 4, 8, 12, 16, 24 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication.
Percentage of Participants With Cumulative Reduction From Baseline to Week 16 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF) Baseline up to Week 16 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline up to Week 16 are reported.
Percentage of Participants With Cumulative Reduction From Baseline to Week 16 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF) Baseline up to Week 16 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline up to Week 16 are reported.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 2, 4, 8, 12, 16, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 16, 24 WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee. WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, where higher score indicates worse response.
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 12, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 12, 24 SF-36v2: standardized survey evaluating 8 domains of functional health and wellbeing (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health). Total score for each domain were scaled 0 (poor health) to 100 (best health), higher scores indicating good health condition. For obtaining physical and mental component scores, z-score for each scale = (observed score - mean score for general 1990 United States \[US\] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score \[better functioning\])/lower (in case of negative z-score \[worse functioning\]) participant's value was relative to the mean of the reference population.
Percentage of Participants With at Least 30% and 50% Reduction From Baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF) Baseline, Week 2, 4, 8, 12, 16, 24 WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.
Change From Baseline in Average Pain Score in the Index Knee at Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 Participants assessed daily average knee pain during the past 24 hours on an 11-point NRS ranging from 0 (no pain) to 10 (worst pain). Baseline score was calculated as the mean of the scores over the 3 days and a weekly mean was calculated using the daily pain scores within each study week. The change from Baseline was calculated using difference between each post-baseline weekly mean and the Baseline mean score.
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12, 24: Baseline Observation Carried Forward (BOCF) Baseline, Week 12, 24 SF-36v2: standardized survey evaluating 8 domains of functional health and wellbeing (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health). Total score for each domain were scaled 0 (poor health) to 100 (best health), higher scores indicating good health condition.
Percentage of Participants Who Used Rescue Medications Week 2, 4, 8, 12, 16, 24 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication.
Amount of Rescue Medication Taken Week 2, 4, 8, 12, 16, 24 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication.
Trial Locations
- Locations (80)
Stamford Therapeutics Consortium
🇺🇸Stamford, Connecticut, United States
Delray Research Associates
🇺🇸Delray Beach, Florida, United States
University Clinical Research Incorporated
🇺🇸Pembroke Pines, Florida, United States
Gulf Coast Research, LLC
🇺🇸Baton Rouge, Louisiana, United States
Clinical Pharmacology Study Group
🇺🇸Worcester, Massachusetts, United States
Dale G. Bramlet, MD, P.L
🇺🇸Saint Petersburg, Florida, United States
Laureate Clinical Reseach Group
🇺🇸Atlanta, Georgia, United States
Palm Beach Research Center
🇺🇸West Palm Beach, Florida, United States
Early Family Practice Center
🇺🇸Fort Valley, Georgia, United States
Javed Rheumatology Associates, Inc.
🇺🇸Newark, Delaware, United States
Tampa Bay Medical Research, Inc.
🇺🇸Clearwater, Florida, United States
Westside Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
Compass Research, LLC
🇺🇸Orlando, Florida, United States
The Arthritis Center
🇺🇸Springfield, Illinois, United States
Advent Clinical Research Centers
🇺🇸Pinellas Park, Florida, United States
AVIVOCLIN Clinical Services
🇺🇸Port Orange, Florida, United States
Jefrey D. Lieberman, MD, PC
🇺🇸Decatur, Georgia, United States
North Georgia Clinical Research
🇺🇸Woodstock, Georgia, United States
North Georgia Internal Medicine
🇺🇸Woodstock, Georgia, United States
Sonora Clinical Research
🇺🇸Boise, Idaho, United States
Memorial Health System, Inc./ Michiana Arthritis & Osteoporosis Center
🇺🇸South Bend, Indiana, United States
Northwest Indiana Center for Clinical Research
🇺🇸Valparaiso, Indiana, United States
Memorial Health System, Inc.
🇺🇸South Bend, Indiana, United States
Arthritis Center of Lexington
🇺🇸Lexington, Kentucky, United States
Bluegrass Community Research, Inc
🇺🇸Lexington, Kentucky, United States
David H. Neustadt P.S.C.
🇺🇸Louisville, Kentucky, United States
Office of Peter A. Holt, MD
🇺🇸Baltimore, Maryland, United States
The Center for Rheumatology and Bone Research
🇺🇸Wheaton, Maryland, United States
Mansfield Health Center
🇺🇸Mansfield, Massachusetts, United States
KMED Research
🇺🇸Saint Clair Shores, Michigan, United States
Medical Advanced Pain Specialists
🇺🇸Edina, Minnesota, United States
Mercy Health Research
🇺🇸Saint Louis, Missouri, United States
Albuquerque Clinical Trials, Inc.
🇺🇸Albuquerque, New Mexico, United States
New Mexico Clinical Research & Osteoporosis Center, Incorporated
🇺🇸Albuquerque, New Mexico, United States
Health Sciences Research Center at Asthma & Allergy Assoc., PC
🇺🇸Elmira, New York, United States
Health Sciences Research Center at Asthma and Allergy Associates P.C.
🇺🇸Ithaca, New York, United States
The Medical Research Network, LLC
🇺🇸New York, New York, United States
Prem C. Chatpar, MD, LLC
🇺🇸Plainview, New York, United States
AAIR Research Center
🇺🇸Rochester, New York, United States
Arthristis and Osteoporosis Consultants of the Carolinas
🇺🇸Charlotte, North Carolina, United States
Pharmquest
🇺🇸Greensboro, North Carolina, United States
Piedmont Medical Research Associates
🇺🇸Winston-Salem, North Carolina, United States
C.A.R.E. Center
🇺🇸Raleigh, North Carolina, United States
Southwest Rheumatology and Research Group, LLC
🇺🇸Middleburg Heights, Ohio, United States
EPIC Imaging West
🇺🇸Beaverton, Oregon, United States
East Penn Rheumatology Associates, PC
🇺🇸Bethlehem, Pennsylvania, United States
Brandywine Clinical Research
🇺🇸Downingtown, Pennsylvania, United States
Altoona Center for Clinical Research
🇺🇸Duncansville, Pennsylvania, United States
Walter Chase, MD
🇺🇸Austin, Texas, United States
Metroplex Clinical Research Center
🇺🇸Dallas, Texas, United States
Charlottesville Medical Research
🇺🇸Charlottesville, Virginia, United States
Clinical Trials Northwest
🇺🇸Yakima, Washington, United States
Neurorehabilitation & Diagnostic Services
🇺🇸Miami, Florida, United States
South Medical Research Group
🇺🇸Miami, Florida, United States
Clinical Research Consortium
🇺🇸Las Vegas, Nevada, United States
Hilltop Physicians Inc, Hightop Medical Research Center
🇺🇸Cincinnati, Ohio, United States
Texas Arthritis Research Center, PA
🇺🇸San Antonio, Texas, United States
Diagnostics Research Group
🇺🇸San Antonio, Texas, United States
MAPS Applied Research Center
🇺🇸Edina, Minnesota, United States
Arizona Research Center, Inc.
🇺🇸Phoenix, Arizona, United States
Health Research Institute
🇺🇸Oklahoma City, Oklahoma, United States
EPIC Imaging East:
🇺🇸Portland, Oregon, United States
Covance CRU, Inc.
🇺🇸Portland, Oregon, United States
Innovative Research of West Florida, Inc.
🇺🇸Clearwater, Florida, United States
Arthritis Associates Inc.
🇺🇸Peabody, Massachusetts, United States
Clinical Research Center of Connecticut
🇺🇸Danbury, Connecticut, United States
The Arthritis and Osteoporosis Center of Maryland
🇺🇸Frederick, Maryland, United States
Pharmax Research Clinic, LLC
🇺🇸Miami, Florida, United States
Avail Clinical Rearch, LLC
🇺🇸DeLand, Florida, United States
Maine Research Associates
🇺🇸Auburn, Maine, United States
Arthritis and Diabetes Clinic
🇺🇸Monroe, Louisiana, United States
Arthritis Associates of South Florida, Clinical Research Center
🇺🇸Delray Beach, Florida, United States
Avail Clinical Research
🇺🇸DeLand, Florida, United States
The Baton Rouge Clinic
🇺🇸Baton Rouge, Louisiana, United States
Health Concepts
🇺🇸Rapid City, South Dakota, United States
Ann Arbor Clinical Research
🇺🇸Ann Arbor, Michigan, United States
Appalachian Medical Research
🇺🇸Johnson City, Tennessee, United States
Comprehensive Clinical Research
🇺🇸Berlin, New Jersey, United States
Pharmacotherapy Research Associates,Inc
🇺🇸Zanesville, Ohio, United States
Radiant Research
🇺🇸San Antonio, Texas, United States